SECsense Logo

Regeneron Pharmaceuticals 8-K Report: Key Insights from April 29, 2025 Filing

$REGN
Form 8-K
Filed on: 2025-04-29
Source
Regeneron Pharmaceuticals 8-K Report: Key Insights from April 29, 2025 Filing

Here are the key insights extracted from the provided section of the financial report:

  1. Entity Information:
  • Company Name: Regeneron Pharmaceuticals, Inc.
  • CIK: 0000872589
  • SEC File Number: 000-19034
  • EIN: 13-3444607
  • Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
  • Phone Number: 914-847-7000
  1. Filing Details:
  • Filing Type: 8-K
  • Filing Date: April 29, 2025
  1. Stock Information:
  • Type of Stock: Common Stock
  • Par Value: $0.001 per share
  • Ticker Symbol: REGN
  • Exchange: NASDAQ
  1. Period of Report:
  • Report Date: April 29, 2025
  • The report is for a single day period, indicating it may cover a significant event or announcement made on that specific date.

Insights:

  • The filing suggests that Regeneron Pharmaceuticals may have disclosed important information, as is typical for an 8-K report, which is often used to announce major events that shareholders should be aware of.
  • The precise timing of the filing (same date for start and end) indicates a specific disclosure rather than a broader financial summary over a longer period.
  • Being listed on NASDAQ under the ticker REGN indicates the company's active participation in the stock market, which could be relevant for investors and analysts tracking its performance.

This information could be relevant for investors, analysts, and stakeholders interested in understanding Regeneron's current status and any significant developments communicated through the filing.